Information on the price of Januvia is not available in the provided context.
What is Januvia?
Januvia, with the active ingredient sitagliptin, is an oral medication prescribed to improve blood sugar control in adults with type 2 diabetes [1]. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors [2].
How does Januvia work?
Januvia functions by increasing the levels of incretin hormones in the body. These hormones help to regulate blood glucose by stimulating the pancreas to release more insulin and reducing the amount of glucose the liver produces [1][2].
When does Januvia's patent expire?
The patent for Januvia is set to expire in 2026 [3]. This information is available through patent tracking resources like DrugPatentWatch.com [3].
What happens after Januvia's patent expires?
Following patent expiration, other companies may be able to produce and market generic versions of Januvia, potentially leading to lower prices [4].
Are there alternatives to Januvia?
Yes, several other medications are available for type 2 diabetes management, including other DPP-4 inhibitors, metformin, sulfonylureas, and newer classes of drugs like GLP-1 receptor agonists and SGLT2 inhibitors [2]. The choice of treatment depends on individual patient needs and medical history.
Who makes Januvia?
Januvia is manufactured by Merck & Co. [1].
What are the risks associated with Januvia?
Potential side effects of Januvia can include upper respiratory tract infection, headache, and an increased risk of pancreatitis [1]. Patients with a history of pancreatitis should discuss this with their doctor before starting Januvia [1].
Sources:
[1] https://www.janssen.com/us/our-products/janssen-products-list/januvia
[2] https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis-treatment/drc-20351199
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/drugs/generic-drugs